OMER

Omeros Corp

20.13

Sep 25 • 5:21 AM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR CRNX RYTM INCY BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF XPH IWN SCHA VTWO IHE VFMO IWO

Index	RUT
Market Cap	1.46B
Enterprise Value	1.62B
Income	124.83M
Sales	38.42M
Book/sh	-0.71
Cash/sh	1.82
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	175
IPO	Oct 08, 2009

P/E	14.00
Forward P/E	19.05
PEG	-
P/S	37.93
P/B	-
P/C	11.04
P/FCF	-
EV/EBITDA	-
EV/Sales	42.22
Quick Ratio	1.94
Current Ratio	1.95
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	1.44
EPS next Y	1.06
EPS next Q	0.03
EPS this Y	1913.33%
EPS next Y	16.54%
EPS next 5Y	-
EPS past 3/5Y	- 53.45%
Sales past 3/5Y	- -
EPS Y/Y TTM	181.47%
Sales Y/Y TTM	-
EPS Q/Q	134.01%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	155.91% 124.79%

Insider Own	4.29%
Insider Trans	-3.82%
Inst Own	51.19%
Inst Trans	8.42%
ROA	47.82%
ROE	-
ROIC	67.05%
Gross Margin	94.02%
Oper. Margin	-189.53%
Profit Margin	324.88%
SMA20	6.71%
SMA50	25.65%
SMA200	57.46%
Trades

Shs Outstand	72.09M
Shs Float	69.29M
Short Float	18.03%
Short Ratio	6.34
Short Interest	12.49M
52W High	21.24 -5.23%
52W Low	4.05 396.42%
Volatility	4.97% 4.75%
ATR (14)	0.90
RSI (14)	62.83
Beta	2.57
Rel Volume	0.00
Avg Volume	1.97M
Volume	161

Perf Week	12.65%
Perf Month	10.48%
Perf Quarter	132.18%
Perf Half Y	95.44%
Perf YTD	17.21%
Perf Year	359.59%
Perf 3Y	573.24%
Perf 5Y	26.76%
Perf 10Y	72.94%
Recom	1.50
Target Price	36.67
Prev Close	20.13
Price	20.13
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$22
Jun-10-25	Initiated	H.C. Wainwright	Buy	$9
Dec-23-24	Initiated	D. Boral Capital	Buy	$36
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$9
Dec-08-22	Downgrade	UBS	Buy → Neutral	$12 → $2
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $3
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral	$12 → $4
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Sep-27-21	Initiated	JP Morgan	Neutral	$15
Feb-01-21	Initiated	UBS	Buy	$25
Oct-20-20	Initiated	BofA Securities	Buy	$21
Aug-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $32
Aug-14-20	Reiterated	Maxim Group	Buy	$25 → $20
May-06-19	Initiated	Cantor Fitzgerald	Overweight	$26
Jul-12-18	Initiated	Seaport Global Securities	Buy	$30
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral	$47 → $19
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy	$30

Show Previous Ratings

Sep-22-26 01:50PM	NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak Whats Driving Investors Enthusiasm Today? (Stocktwits) +13.85%
Aug-12-26 09:56PM	Omeros Corporation Q2 2026 Earnings Call Summary (Moby) +26.55%
05:08PM	OMER Stock Soars 24% After-Hours On YARTEMLEA Sales Momentum, Debt Reduction And Share Buybacks (Stocktwits)
04:13PM	Omeros: Q2 Earnings Snapshot (Associated Press)
04:02PM	Omeros Corporation Reports Second Quarter 2026 Financial Results (Business Wire)
08:00AM	Loading…
Aug-10-26 08:00AM	Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 (Business Wire)
Aug-03-26 02:41PM	OMER Stock Gains 4% CMS Green-Lights $287K Add-On Payments For Transplant Drug (Stocktwits) +6.08%
08:30AM	CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA (Business Wire)
Jul-27-26 12:25PM	AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst A Look At Some Key Highlights (Stocktwits) +15.83%
Jun-26-26 08:33AM	Why Is OMER Stock Falling Today? (Stocktwits) -19.12%
08:30AM	Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA (Business Wire)
Jun-15-26 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +6.81%
May-14-26 08:30AM	Omeros Corporation Q1 2026 Earnings Call Summary (Moby) -7.65%
01:02AM	Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YARTEMLEA Launch and Strategic ... (GuruFocus.com)
May-13-26 04:17PM	Omeros: Q1 Earnings Snapshot (Associated Press)
04:02PM	Loading…
04:02PM	Omeros Corporation Reports First Quarter 2026 Financial Results (Business Wire)
May-11-26 04:02PM	Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 (Business Wire)
Apr-16-26 08:45AM	CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA (narsoplimab-wuug) (Business Wire)
Apr-10-26 08:11PM	Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect? (Quartz)
Apr-01-26 08:30AM	Omeros Corporation Q4 2025 Earnings Call Summary (Moby) +14.39%
Mar-31-26 11:02PM	Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ... (GuruFocus.com) +7.65%
04:22PM	Omeros: Q4 Earnings Snapshot (Associated Press)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results (Business Wire)
Mar-26-26 08:45AM	Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 (Business Wire)
Mar-21-26 03:23AM	Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment (Business Wire)
Feb-17-26 08:45AM	Omeros Announces Successful Primate Study in OncotoX-AML Drug Program (Business Wire)
Jan-27-26 09:00AM	Omeros Announces First Commercial Sales of YARTEMLEA (Business Wire) +9.89%
Dec-29-25 10:57AM	Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA (Zacks) +5.47%
Dec-26-25 06:36PM	Omeros Announces New Date for YARTEMLEA Approval Conference Call (Business Wire)
Dec-24-25 05:42PM	Why Omeros Stock Skyrocketed Today (Motley Fool) +75.54%
09:00AM	Loading…
09:00AM	FDA Approves Omeros' YARTEMLEA - First and Only Therapy Indicated for TA-TMA (Business Wire)
Dec-10-25 02:15PM	Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz (Insider Monkey)
Dec-08-25 08:24AM	Do You Believe Omeros Corporation's (OMER) New Monoclonal Antibody Has Strong Chances of Approval? (Insider Monkey) +5.07%
Dec-01-25 08:30AM	Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) (Business Wire)
Nov-14-25 12:02AM	Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges (GuruFocus.com) +25.32%
Nov-13-25 05:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance) -8.85%
04:11PM	Omeros Corporation Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-11-25 08:30AM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 (Business Wire)
Oct-26-25 06:05AM	Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? (Insider Monkey)
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
Oct-22-25 07:41AM	Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk (Insider Monkey)
Oct-16-25 12:16PM	Novo Nordisk snaps up Omeros rare disease asset for up to $2.1bn (Pharmaceutical Technology) -5.66%
11:10AM	NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio (Zacks)
08:30AM	Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group (Business Wire)
03:39AM	A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? (Motley Fool)
Oct-15-25 04:12PM	Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk (Investor's Business Daily) +154.15%
03:58PM	Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run? (Barchart)
12:49PM	Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk (Investor's Business Daily)
11:25AM	Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion (The Wall Street Journal)
10:52AM	Novo wagers up to $2.1B on Omeros rare disease drug (BioPharma Dive)
09:17AM	Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug (The Wall Street Journal)
Sep-02-25 08:45AM	Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program (Business Wire)
Aug-15-25 03:24AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com) +7.04%
Aug-14-25 04:08PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-11-25 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 (Business Wire)
Jul-25-25 08:00AM	Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering (Business Wire) +6.69%
Jun-27-25 08:30AM	Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA (Business Wire)
Jun-24-25 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +5.96%
Jun-03-25 09:35AM	Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) (Zacks)
May-16-25 08:13AM	Q1 2025 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -18.61%
03:13AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com)
May-15-25 04:34PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Omeros Corporation Reports First Quarter 2025 Financial Results (Business Wire)
May-12-25 05:05PM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 (Business Wire) -38.59% +16.73%
08:41AM	Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 (Business Wire)
May-06-25 09:16AM	FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date (Business Wire) -6.90%
Apr-10-25 09:10AM	Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros Proprietary OncotoX-AML Clinical Program (Business Wire) -9.85%
Apr-08-25 09:00AM	Omeros Corporation To Introduce Its Proprietary T-CAT Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases (Business Wire) -12.55%
Apr-01-25 09:27AM	Q4 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 08:57PM	Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Mar-26-25 09:15AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 (Business Wire) -6.99%
Mar-24-25 07:58AM	Omeros to activate site for Phase III programme of zaltenibart for PNH (Clinical Trials Arena)
Mar-21-25 09:15AM	Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program (Business Wire)
Mar-13-25 09:00AM	Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Companys OMS527 Program to Treat Cocaine Use Disorder (Business Wire)
Feb-21-25 09:21AM	Omeros announces results for narsoplimab expanded access program (TipRanks)
Feb-20-25 09:10AM	Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA (Business Wire)
Feb-14-25 09:00AM	Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings (Business Wire)
Feb-10-25 09:00AM	Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program (Business Wire)
Jan-16-25 09:15AM	Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint (Business Wire)
Dec-19-24 10:46AM	Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges (GuruFocus.com) +37.27%
09:15AM	Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint - Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA (Business Wire)
Dec-10-24 12:22PM	Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges (Insider Monkey) -7.38%
08:45AM	Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting (Business Wire)
Dec-02-24 08:45AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +5.29%
Nov-22-24 02:31PM	Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News (GuruFocus.com) +41.14%
Nov-21-24 09:15AM	Omeros Corporation Provides Update on Progress Toward BLA Resubmission (Business Wire) +28.19%
Nov-14-24 02:01PM	Q3 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) +65.87%
02:15AM	Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments (GuruFocus.com)
Nov-13-24 04:17PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-11-24 04:11PM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 (Business Wire)
Oct-24-24 08:45AM	FDA Grants Rare Pediatric Disease Designation to Omeros MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy (Business Wire)
Aug-07-24 05:16PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance) -5.03% -5.78%
04:02PM	Omeros Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 (Business Wire) -10.68%
Jun-04-24 09:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -6.16%

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Co-FounderDr. Gregory A. Demopulos M.D.

VP of FinanceMr. David J. Borges

VPMr. Peter B. Cancelmo J.D.

Ph.D.Dr. Pamela Pierce Palmer M.D.

Ph.D.Dr. George A. Gaitanaris M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Borges David J.	VP, Finance & CAO	Sep 23 '26	Option Exercise	15.58	10,000	155,800	10,000	Sep 24 09:00 PM
Borges David J.	VP, Finance & CAO	Sep 22 '26	Option Exercise	3.44	10,000	34,350	10,000	Sep 24 09:00 PM
Borges David J.	VP, Finance & CAO	Sep 23 '26	Sale	20.95	10,000	209,500	0	Sep 24 09:00 PM
Borges David J.	VP, Finance & CAO	Sep 22 '26	Sale	20.95	10,000	209,500	0	Sep 24 09:00 PM
DAVID BORGES	Officer	Sep 23 '26	Proposed Sale	21.05	14,927	314,213		Sep 23 04:20 PM
DAVID BORGES	Officer	Sep 22 '26	Proposed Sale	18.49	10,000	184,900		Sep 22 04:15 PM
Cancelmo Peter B	VP, General Counsel	Aug 28 '26	Option Exercise	2.94	25,000	73,500	25,200	Sep 01 04:41 PM
Cancelmo Peter B	VP, General Counsel	Aug 31 '26	Option Exercise	2.94	25,000	73,500	25,200	Sep 01 04:41 PM
Cancelmo Peter B	VP, General Counsel	Aug 28 '26	Sale	18.65	25,000	466,128	200	Sep 01 04:41 PM
Cancelmo Peter B	VP, General Counsel	Aug 31 '26	Sale	18.54	25,000	463,540	200	Sep 01 04:41 PM
PETER CANCELMO	Officer	Aug 31 '26	Proposed Sale	18.54	25,000	463,540		Aug 31 04:21 PM
PETER CANCELMO	Officer	Aug 28 '26	Proposed Sale	18.65	25,000	466,128		Aug 28 04:34 PM
HANISH ARNOLD C	Director	Aug 27 '26	Option Exercise	14.95	10,000	149,475	10,000	Aug 28 04:31 PM
HANISH ARNOLD C	Director	Aug 26 '26	Option Exercise	15.81	5,000	79,050	5,000	Aug 28 04:31 PM
HANISH ARNOLD C	Director	Aug 27 '26	Sale	18.95	10,000	189,462	0	Aug 28 04:31 PM
HANISH ARNOLD C	Director	Aug 26 '26	Sale	18.53	5,000	92,632	0	Aug 28 04:31 PM
ARNOLD HANISH	Director	Aug 27 '26	Proposed Sale	18.95	10,000	189,462		Aug 27 04:12 PM
ARNOLD HANISH	Director	Aug 26 '26	Proposed Sale	18.83	5,000	94,132		Aug 26 04:16 PM
Borges David J.	VP, Finance & CAO	Aug 21 '26	Option Exercise	3.52	10,000	35,247	10,000	Aug 25 05:40 PM
Borges David J.	VP, Finance & CAO	Aug 24 '26	Option Exercise	2.94	906	2,664	906	Aug 25 05:40 PM
Borges David J.	VP, Finance & CAO	Aug 21 '26	Sale	18.95	10,000	189,500	0	Aug 25 05:40 PM
Borges David J.	VP, Finance & CAO	Aug 24 '26	Sale	19.10	906	17,305	0	Aug 25 05:40 PM
Cable Thomas J.	Director	Aug 20 '26	Option Exercise	2.96	15,000	44,475	50,067	Aug 21 05:34 PM
Cable Thomas J.	Director	Aug 20 '26	Sale	18.45	15,000	276,772	35,067	Aug 21 05:34 PM
DAVID BORGES	Officer	Aug 21 '26	Proposed Sale	18.63	10,906	203,179		Aug 21 04:42 PM
THOMAS CABLE	Director	Aug 20 '26	Proposed Sale	18.45	15,000	276,772		Aug 20 04:23 PM
Borges David J.	VP, Finance & CAO	Aug 13 '26	Option Exercise	3.93	5,000	19,650	5,000	Aug 17 07:42 PM
Borges David J.	VP, Finance & CAO	Aug 13 '26	Sale	16.95	5,000	84,750	0	Aug 17 07:42 PM
DAVID BORGES	Officer	Aug 13 '26	Proposed Sale	13.71	5,000	68,550		Aug 13 04:36 PM
Cable Thomas J.	Director	May 22 '26	Option Exercise	10.84	7,500	81,300	42,567	May 27 06:21 PM
Cable Thomas J.	Director	May 22 '26	Sale	11.61	7,500	87,039	35,067	May 27 06:21 PM
Thomas Cable	Director	May 22 '26	Proposed Sale	11.96	7,500	89,700		May 22 04:33 PM
Demopulos Gregory A MD	Chairman, CEO & President	Feb 18 '26	Option Exercise	10.27	400,000	4,108,000	1,826,986	Feb 20 09:40 PM
Borges David J.	VP, Finance & CAO	Jan 13 '26	Option Exercise	3.06	30,000	91,800	30,000	Jan 14 05:25 PM
Borges David J.	VP, Finance & CAO	Jan 12 '26	Sale	12.72	30,000	381,600	0	Jan 14 05:25 PM
Borges David J.	VP, Finance & CAO	Jan 13 '26	Sale	12.31	30,000	369,315	0	Jan 14 05:25 PM
DAVID J BORGES	Officer	Jan 13 '26	Proposed Sale	12.31	30,000	369,315		Jan 13 04:31 PM
DAVID J BORGES	Officer	Jan 12 '26	Proposed Sale	12.72	30,000	381,600		Jan 12 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OMER

Omeros Corp

Upgrade your Finviz experience